



Ruth Demmer-Steingruber

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Ruth Demmer-Steingruber
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 6875
Ruth.Demmer-Steingruber@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

study nurse

Publications (4)

Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. *Swiss Med Wkly* 2023; 153:40090.

Früh M, Gillessen Sommer S, Cerny T, Demmer-Steingruber R, D'Addario G. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2008; 62:344-50.

Strasser F, Demmer-Steingruber R, Böhme C, Schmitz S, Thürlimann B, Cerny T, Gillessen Sommer S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. *The Oncologist* 2008; 13:337-46.

Strasser F, Cerny T, Von Moss R, Brändle M, Holst B, Kaufmann K, Tschöp M, Büche D, Thürlimann B, Maeder M, Lutz T, Demmer-Steingruber R. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. *BJC* 2008; 98:300-8.

Projects (24)

NIS-KOLON (CNIS793E12201)

Clinical Studies - Nov 16, 2022 - Dec 31, 2099

Ongoing

Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien

Clinical Studies - Oct 1, 2021 - Feb 28, 2021

Automatically Closed

BMS CA224-104 Relatilimab

Clinical Studies - Jul 30, 2021 - Dec 31, 2099

Ongoing

SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase II trial

Clinical Studies - Jul 14, 2021 - Dec 31, 2099

Ongoing

Swiss Soliris® and Ultomiris® Reimbursement Registry SSURR: An observational registry for capturing data of patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) who are treated with Soliris® (eculizumab) or Ultomiris® (ravulizumab)

Clinical Studies - Jan 1, 2021 - Dec 31, 2030

Ongoing

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Studies - Jul 10, 2020 - Mar 11, 2024

Completed

Achilles MO40379

Clinical Studies - Jan 29, 2020 - Dec 31, 2030

Ongoing

Randomized Phase II Trial on fitness and comorbidity-tailored treatment in elderly patients with newly diagnosed primary CNS Lymphoma (FIORELLA Trial)

Clinical Studies - Jun 7, 2019 - Dec 31, 2099

Ongoing

Prospective Observational international Registry of Patients with newly diagnosed peripheral T-Cell Lymphoma

Clinical Studies - Jan 1, 2019 - Dec 31, 2030

Ongoing

IBCSG 55-17 "Touch" Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer

Clinical Studies - Dec 4, 2018 - Jun 7, 2023

Completed

TRIANGLE

Clinical Studies - Feb 20, 2018 - Dec 31, 2099

Ongoing

SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

Clinical Studies - Jun 3, 2016 - Dec 31, 2099

Ongoing

MK-3475-091; PEARLS

Clinical Studies - Mar 30, 2016 - Dec 31, 2099

Ongoing

A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III

Clinical Studies - Oct 26, 2015 - Dec 31, 2099

Ongoing

POSITIVE IBCSG 48-14

Clinical Studies - Mar 27, 2015 - Dec 31, 2099

Ongoing

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)

Clinical Studies - Aug 7, 2014 - Dec 31, 2099

Ongoing

Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

Clinical Studies - Apr 16, 2013 - Aug 30, 2023

Completed

Biomarkes Cancer Cachexia in Urin and Blood

Fundamental Research - Oct 14, 2012 - Dec 15, 2012

Aborted

Aphinity

Clinical Studies - Mar 13, 2012 - Dec 31, 2019

Ongoing

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (STP)

Clinical Studies - Sep 3, 2009 - Dec 31, 2019

Ongoing

A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer

Clinical Studies - Sep 3, 2009 - Dec 31, 2019

Ongoing

Eine Substudie zur TEXT-Studie zur Untersuchung der Knochendichte und Analyse von Knochenmarkern und Wachstumsfaktoren Substudie zur Studie zu Tamoxifen und Exemestan (IBCSG 25-02 / BIG 3-02 TEXT)

Clinical Studies - Sep 3, 2009 - Dec 31, 2019

Ongoing

Prospective evaluation of the predictive value of PET in patients with diffuse large B-cell-lymphoma under R-CHOP-14. A multicenter study

Clinical Studies - Jan 28, 2008 - Sep 28, 2011

Automatically Closed

Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial

Clinical Studies - Oct 25, 2006 - Oct 25, 2010

Completed